Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

Condition:   Chronic Migraine Intervention:   Drug: Emgality 120 MG in 1 ML Prefilled Syringe Sponsors:   Beth Israel Deaconess Medical Center;   Eli Lilly and Company Not yet recruiting

Source: ClinicalTrials.gov - February 17, 2020 Category: Research Source Type: clinical trials